Earnings summaries and quarterly performance for EyePoint.
Executive leadership at EyePoint.
Board of directors at EyePoint.
Research analysts who have asked questions during EyePoint earnings calls.
Yatin Suneja
Guggenheim Partners
7 questions for EYPT
Also covers: ACAD, ARGX, AXSM +11 more
YC
Yi Chen
H.C. Wainwright & Co.
6 questions for EYPT
Also covers: ANGO, APDN, BLFS +22 more
DC
Debanjana Chatterjee
JonesTrading Institutional Services
5 questions for EYPT
Also covers: ABSI, CLSD, KALV +2 more
Jennifer Kim
Cantor Fitzgerald
5 questions for EYPT
Also covers: BLTE, CPRX, INSM +1 more
Tessa Romero
JPMorgan Chase & Co.
5 questions for EYPT
Also covers: ACAD, AGIO, CYTK +5 more
YN
Yigal Nochomovitz
Citigroup Inc.
5 questions for EYPT
Also covers: ALDX, APLS, ARCT +22 more
CK
Colleen Kusy
Robert W. Baird & Co.
4 questions for EYPT
Also covers: APLS, BPMC, CHRS +6 more
Graig Suvannavejh
Mizuho Securities
4 questions for EYPT
Also covers: ADAP, ADVM, ALEC +12 more
GH
Greg Harrison
RBC Capital Markets
4 questions for EYPT
Also covers: ADCT, APLS, BBIO +3 more
KY
Kambiz Yazdi
Jefferies
4 questions for EYPT
Also covers: ARQT, LQDA, PRAX
TV
Tyler Van Buren
TD Cowen
4 questions for EYPT
Also covers: ADVM, ALLO, ARGX +13 more
Nick Quartapella
Robert W. Baird & Co.
3 questions for EYPT
YJ
Yale Jen
Laidlaw & Company (UK) Ltd.
3 questions for EYPT
Also covers: AFMD, ALDX, ARCT +14 more
DG
Daniil Gataulin
Chardan
2 questions for EYPT
Also covers: CGTX, CLSD, KOD +3 more
LW
Lisa Walter
RBC Capital Markets
2 questions for EYPT
Also covers: APLS, OCUL, RGNX +3 more
Gregory Harrison
Scotiabank
1 question for EYPT
Also covers: AGIO, APLS, GERN +3 more
GS
Greg Silvaniouve
Mizuho Financial Group
1 question for EYPT
GS
Greg Silvanouve
Mizuho
1 question for EYPT
Also covers: INSM
Recent press releases and 8-K filings for EYPT.
EyePoint Pharmaceuticals Provides Updates on Clinical Programs and Financial Outlook
EYPT
Guidance Update
New Projects/Investments
Product Launch
- EyePoint Pharmaceuticals expects data readout for its LUGANO wet AMD trial by mid-2026, followed by the LUCIA trial a few months later, and anticipates data from its DME trials (COMO and CAPRI) by the end of 2027.
- The company reported $300 million in cash at the end of 2025, providing a cash runway into Q4 2027, which fully funds its ongoing pivotal programs, manufacturing scale-up, and NDA submission.
- EyePoint's lead asset, DURAVYU, is an intravitreal insert designed for six-month dosing in wet AMD and DME, targeting U.S. markets valued at $12 billion and $3 billion, respectively.
- The company plans to self-commercialize DURAVYU in the United States and has observed no safety signals to date with the drug in clinical trials.
Feb 12, 2026, 4:00 PM
EyePoint Provides Update on DURAVYU Clinical Programs and Financial Outlook
EYPT
Guidance Update
New Projects/Investments
Product Launch
- EyePoint's lead asset, DURAVYU (vorolanib), a small molecule tyrosine kinase inhibitor delivered via Durasert E technology, is designed for at least six-month dosing in wet AMD and DME.
- Data from the LUGANO Phase 3 trial for wet AMD is expected mid-year 2026, with the LUCIA trial following a few months later, aiming for non-inferiority versus aflibercept.
- The company initiated Phase 3 trials (COMO and CAPRI) for DME in Q4 2025, with first patient dosing guided for Q1 2026 and potential data by the end of 2027.
- EyePoint ended 2025 with $300 million in cash, providing a cash runway into Q4 2027, which fully funds its ongoing pivotal programs, manufacturing scale-up, and NDA submission.
- EyePoint plans an independent U.S. launch for DURAVYU, targeting the $12 billion wet AMD market and the $3 billion DME market.
Feb 12, 2026, 4:00 PM
EyePoint Provides Update on DURAVYU Clinical Trials and Financial Position
EYPT
Guidance Update
New Projects/Investments
Product Launch
- EyePoint's lead asset, DURAVYU, a six-month intravitreal injection for wet AMD and DME, is progressing through pivotal trials, with LUGANO Phase 3 wet AMD trial data expected mid-year 2026 and LUCIA a few months later.
- The company initiated Phase 3 DME trials (COMO and CAPRI) in Q4 2025, with first patient dosing expected in Q1 2026 and data potentially by the end of 2027.
- EyePoint ended 2025 with $300 million in cash, providing a cash runway into Q4 2027, which fully funds its ongoing pivotal programs, manufacturing scale-up, and NDA submission.
- The company plans to self-launch DURAVYU in the United States for wet AMD, targeting a significant market opportunity.
Feb 12, 2026, 4:00 PM
EyePoint Provides Update on Duraview Clinical Trials and Financial Position
EYPT
New Projects/Investments
Guidance Update
- EyePoint's lead product, Duraview, is in Phase III trials for wet age-related macular degeneration (AMD), with both trials fully enrolled and top-line data anticipated mid-year 2026.
- The Duraview Phase III program for diabetic macular edema (DME) is underway, with the first patients expected to be dosed in Q1 2026.
- As of the end of 2025, EyePoint had approximately $300 million in cash, providing a financial runway past data into the end of 2027 and funding all ongoing Phase III trials.
- The company has a commercial manufacturing facility in Northbridge, Massachusetts, which has been operational for over a year and is preparing for pre-approval inspection and commercial success.
- Duraview is highlighted for its multi-mechanism of action (VEGF, PDGF, and IL-6 inhibition), at least six-month durability, and the convenience of room temperature storage.
Jan 13, 2026, 3:30 PM
EyePoint Provides Update on Duraview Phase III Trials and Financial Position at JPMorgan Healthcare Conference
EYPT
New Projects/Investments
Guidance Update
- EyePoint's lead product, Duraview, a sustained-release drug for retinal disease, is in Phase III trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
- The company anticipates top-line data from its wet AMD trials (Lugano and Lucia) starting mid-year 2026, and plans to dose the first patients in its DME trials (COMO and CAPRI) in Q1 2026.
- As of the end of 2025, EyePoint reported approximately $300 million in cash, providing a financial runway into Q4 2027, which funds all ongoing Phase III trials.
- Duraview is characterized by its multi-mechanism of action (MOA), targeting VEGF, PDGF, and IL-6, and demonstrated six-month durability in previous trials with a favorable safety profile.
Jan 13, 2026, 3:30 PM
EyePoint Provides Update on DURAVYU Clinical Trials and Financial Position
EYPT
New Projects/Investments
Guidance Update
- EyePoint's lead product, DURAVYU, is in Phase III trials for wet age-related macular degeneration (AMD) with top-line data expected starting mid-2026, and Phase III trials for diabetic macular edema (DME) are underway with first patients to be dosed in Q1 2026.
- The company reported approximately $300 million in cash as of the end of 2025, providing a financial runway well past data into the end of 2027.
- EyePoint's commercial manufacturing facility in Northbridge, Massachusetts, has been operational for over a year and is preparing for pre-approval inspection and commercial success.
- DURAVYU is a sustained-release drug for retinal disease, offering multi-MOA (VEGF, IL-6, PDGF inhibition) and six-month durability, with a non-inferiority regulatory pathway against Eylea.
Jan 13, 2026, 3:30 PM
EyePoint Pharmaceuticals Provides Update on DURAVYU™ Phase 3 Trials and Financial Runway
EYPT
New Projects/Investments
Guidance Update
- EyePoint Pharmaceuticals' DURAVYU™ (vorolanib intravitreal insert) Phase 3 trials for wet AMD are fully enrolled, with topline data anticipated in mid-2026.
- The Phase 3 DME program is underway, with First Patient In (FPI) expected in Q1 2026.
- The company reported approximately $300 million in cash and investments as of December 31, 2025, providing a runway into Q4 2027.
- DURAVYU™ has demonstrated a favorable safety profile with no related severe adverse events across four clinical trials and offers multi-MOA with 6-month durability for a combined $15B+ global market opportunity in wet AMD and DME.
Jan 13, 2026, 3:30 PM
EyePoint Investor Presentation Highlights DURAVYU Development
EYPT
New Projects/Investments
Guidance Update
Product Launch
- EyePoint's January 2026 investor presentation focuses on its product candidate, DURAVYU.
- DURAVYU is anticipated to be the first-to-market sustained release treatment for wet AMD and is the only TKI in development for DME, with expectations for two potential blockbuster indications.
- The company expects to provide updates on the timing for DME clinical trial enrollment and the availability of wet AMD clinical data.
- Key risks include uncertainties in clinical development, regulatory approval processes, and the sufficiency of the company's cash and cash equivalents.
Jan 12, 2026, 12:00 PM
EyePoint Reports Preliminary Cash and Key Clinical Milestones
EYPT
Guidance Update
New Projects/Investments
- EyePoint, Inc. reported preliminary cash and investments of approximately $300 million as of December 31, 2025, which is expected to provide a cash runway into the fourth quarter of 2027.
- The company completed an underwritten public offering in October 2025, generating $172.5 million in gross proceeds.
- Topline data from the Phase 3 wet Age-Related Macular Degeneration (AMD) program for DURAVYU is anticipated beginning in mid-2026.
- First patient dosing for the Phase 3 Diabetic Macular Edema (DME) program for DURAVYU is expected in Q1 2026.
Jan 7, 2026, 12:05 PM
EyePoint Pharmaceuticals Announces Positive DSMC Recommendation for DURAVYU Phase 3 Trials
EYPT
New Projects/Investments
Product Launch
- EyePoint Pharmaceuticals received a positive recommendation from the independent Data Safety Monitoring Committee (DSMC) for its pivotal Phase 3 program evaluating DURAVYU for wet age-related macular degeneration (wet AMD).
- The DSMC recommended that both the LUGANO and LUCIA trials continue as planned with no modifications to the protocol, citing no safety signals in the masked safety data.
- The company anticipates reporting topline 56-week data for the LUGANO trial in mid-2026, with LUCIA data to follow.
- First patient dosing for DURAVYU in Phase 3 trials for diabetic macular edema (DME) is expected in the first quarter of 2026.
Nov 19, 2025, 12:05 PM
Quarterly earnings call transcripts for EyePoint.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more